Friday, January 27, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home CBRNE

Omnibus BAA for Biodefense, Radiation Exposure Countermeasures

by Global Biodefense Staff
February 1, 2017

The National Institute of Allergy and Infectious Diseases (NIAID) will be soliciting proposals under a new Omnibus Broad Agency Announcement (BAA) expected to be formally released on February 21, 2017.

The BAA supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases.

The research areas anticipated to be in the NIAID Omnibus BAA include:

  • Adjuvant Development Program: Advancing novel adjuvants towards licensure for human use through immunological characterization studies and lead compound optimization
  • Radiation/Nuclear Medical Countermeasures: New approaches to mitigate and/or treat tissue injuries arising from exposure to ionizing radiation
  • Radiation/Nuclear Predictive Biomarkers and Biodosimetric Devices: Biodosimetry biomarkers and/or automated high-throughput diagnostic systems to rapidly assess levels and types of radiation exposure using minimally invasive biosamples
  • Broad-spectrum Therapeutic Products for Biodefense, Anti-Microbial Resistant Infections and Emerging Infectious Diseases: Development of broad-spectrum therapeutic products for use in post-event settings following the intentional release of a NIAID Category A, B, or C Priority Pathogen, Zika virus, or in response to naturally-occurring outbreaks of infectious diseases caused by these pathogens.
  • Advanced Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases: Development of vaccines for use in post-event settings following the intentional release of a NIAID Category A, B, or C Priority Pathogen, Zika virus, or in response to naturally-occurring outbreaks of infectious diseases caused by these pathogens.

Further details are available via Solicitation Number: HHS-NIH-NIAID-BAA2017-1.

Tags: BAABiodosimetryNIAIDRadiationSelect Agents

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC